

AquaBounty Technologies, Inc. Announces Results for the Year Ended December 31, 2019

March 10, 2020

MAYNARD, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty" or the "Company"), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, announces the Company's financial results for the year ended December 31, 2019.

Results Highlights:

Operational

- Sylvia Wulf assumed the position of Chief Executive Officer, President, and Director;
- The U.S. Food and Drug Administration ("FDA") lifted its Import Alert, allowing the Company to import its AquAdvantage eggs from its hatchery in Canada to its farm in Indiana;
- The Company's Rollo Bay farm site received two regulatory approvals: FDA approved the farm's hatchery building, and Environment and Climate Change Canada approved the farm's production facility for the commercial grow-out of AquAdvantage Salmon;
- The Company's Indiana farm received two batches of AquAdvantage eggs and is now producing both conventional and AquAdvantage Salmon, bringing total biomass at the farm to 160 tons at year end;
- Closed the Panama demonstration farm;
- Received approval in China to conduct a field trial for AquAdvantage Salmon; and
- Commenced marketing and communications activities, including qualitative and quantitative consumer research in preparation for commercialization.

Financial

- Completed two public offerings of common shares, raising net funds of \$12.4 million;
- The Company's Canadian subsidiary received two construction loan instalments totalling \$900 thousand from the
 Department of Economic Development of the Province of Prince Edward Island and the Atlantic Canada Opportunities
 Agency; and
- Net loss for the year increased to \$13.2 million (2018: \$10.4 million) with the ramp-up of production operations in Indiana and Rollo Bay, increased legal fees in support of the FDA legal challenge, and increased headcount.

Sylvia Wulf, Chief Executive Officer of AquaBounty, commented: "This was a transformative year for AquaBounty, as for the first time in the Company's history we began to grow-out our AquAdvantage Salmon in the United States. Production of both AquAdvantage and conventional salmon at our Indiana farm is progressing on track with conventional salmon harvest commencing in late Q2 this year and AquAdvantage Salmon harvest commencing in Q4. We also took steps during 2019 to strengthen our balance sheet with two successful equity raises and to strengthen our management team with the additions of Dave Melbourne as Chief Commercial Officer and Angela Olsen as General Counsel. We believe we are now well positioned to begin to execute our commercial strategy with the harvest and sale of our salmon from both our Indiana and Rollo Bay farms."

Inquiries:

AquaBounty Technologies, Inc.

Dave Conley, Corporate Communications +1 613 294 3078

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding potential harvest size, initiation of a field trial and any related commercial operations in China, and the potential for and timing of the harvest and sale of our fish from our production farms. Forward-looking statements may be identified with words such as "will," "may," "expect," "plan," "anticipate," "upcoming," "believe," "estimate," or similar terminology, and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. For additional information regarding these and other risks faced by us, please refer to our public filings with the Securities and Exchange Commission ("SEC"), available on the Investors section of our website at www.sec.gov.

As of

	December 31,			31,
		2019		2018
Assets				
Current assets:				
Cash and cash equivalents	\$	2,798,744	\$	3,002,557
Other receivables		55,198		115,982
Inventory		1,232,049		76,109
Prepaid expenses and other current assets		391,162		315,969
Total current assets		4,477,153		3,510,617
Property, plant and equipment, net Right of use assets, net		25,065,836 399,477		23,716,768
Definite-lived intangible assets, net		157,588		171,292
Indefinite-lived intangible assets		101,661		191,800
Other assets Total assets	\$	32,024	\$	80,583 27,671,060
Liabilities and stockholders' equity Current liabilities:				
Accounts payable and accrued liabilities	\$	1,462,809	\$	824,900
Other current liabilities		62,286		20,423
Current debt		163,155		71,613
Total current liabilities		1,688,250		916,936
Long-term lease obligations		352,808		_
Long-term debt Total liabilities		4,432,052 6,473,110		3,519,821 4,436,757
Total natifices		0,473,110		4,430,737
Commitments and contingencies				
Stockholders' equity:				
Common stock, \$0.001 par value, 50,000,000 shares authorized;				
21,635,365, (2018: 15,098,837) shares outstanding		21,635		15,099
Additional paid-in capital		156,241,363		142,707,957
Accumulated other comprehensive loss		(360,160)		(574,186
Accumulated deficit		(132,142,209)		(118,914,567
Total stockholders' equity		23,760,629		23,234,303
Total liabilities and stockholders' equity	\$	30,233,739	\$	27,671,060

AquaBounty Technologies, Inc. Consolidated Statements of Operations and Comprehensive Loss

	 Yea	rs end	ed December	2017	
	2019		2018		2017
Revenues					_
Product Revenues	\$ 186,738	\$	84,518	\$	53,278

Production costs	3,573,858	2,626,353	1,193,566
Sales and marketing	709,023	297,687	799,009
Research and development	2,359,441	3,458,564	3,371,767
General and administrative	6,723,060	4,067,710	3,921,035
Total costs and expenses	13,365,382	10,450,314	9,285,377
Operating loss	(13,178,644)	(10,365,796)	(9,232,099)
Other income (expense)			
Interest expense	(62,988)	(22,257)	(21,537)
Other income (expense), net	13,990	5,994	(5,011)
Total other income (expense)	(48,998)	(16,263)	(26,548)
Net loss	\$ (13,227,642) \$	(10,382,059) \$	(9,258,647)
Other comprehensive income (loss):			
Foreign currency translation gain (loss)	214,026	(360,302)	72,388
Total other comprehensive income (loss)	214,026	(360,302)	72,388
Comprehensive loss	\$ (13,013,616) \$	(10,742,361) \$	(9,186,259)
Earnings per share			
Net loss	\$ (13,227,642) \$	(10,382,059) \$	(9,258,647)
Deemed dividend	\$ — \$	(1,822,873) \$	_
Net loss attributable to common shareholders	\$ (13,227,642) \$	(12,204,932) \$	(9,258,647)
Basic and diluted net loss per share attributable to common shareholders	\$ (0.66) \$	(0.94) \$	(1.06)
Weighted average number of common shares -basic and diluted	20,078,017	13,028,760	8,772,494

AquaBounty Technologies, Inc. Consolidated Statements of Cash Flows

	Years ended December 31,			
	2019	2018	2017	
Operating activities				
Net loss	\$ (13,227,642) \$	(10,382,059) \$	(9,258,647)	
Adjustment to reconcile net loss to net cash used in				
operating activities:				
Depreciation and amortization	1,285,902	843,387	184,946	
Share-based compensation	872,177	263,396	122,134	
Gain on disposal of equipment	(12,133)	(13,233)	(941)	
Loss on asset held for sale	149,800		_	
Impairment loss	103,116		_	
Other non-cash charges	_	(1,364)	_	
Changes in operating assets and liabilities:				
Other receivables	65,002	56,212	(11,440)	
Inventory	(1,154,222)	93,956	(169,991)	
Prepaid expenses and other assets	59,942	289,868	(592,602)	
Accounts payable, accrued liabilities and other liabilities	609,311	(966,928)	625,763	

Net cash used in operating activities		(11,248,747)	(9,816,765)		(9,100,778)
Investing activities					
Purchase of property, plant and equipment		(2,316,809)	(4,009,736)		(18,893,264)
Deposits on equipment purchases		(160,675)	(95,001)		(153,663)
Proceeds from sale of equipment		15,848	23,233		941
Net cash used in investing activities		(2,461,636)	(4,081,504)		(19,045,986)
Financing activities					
Proceeds from issuance of debt		900,767	771,858		256,807
Repayment of term debt		(85,802)	(55,615)		(35,812)
Proceeds from the issuance of common stock and warrants, net		12,395,348	10,616,046		24,989,257
Proceeds from exercise of stock options and warrants, net		272,417	5,116,533		27,502
Net cash provided by financing activities		13,482,730	16,448,822		25,237,754
Effect of exchange rate changes on cash and cash equivalents		23,840	(54,279)		80,018
Net change in cash and cash equivalents		(203,813)	2,496,274		(2,828,992)
Cash and cash equivalents at beginning of period		3,002,557	506,283		3,335,275
Cash and cash equivalents at the end of period	\$	2,798,744	\$ 3,002,557	\$	506,283
Supplemental disclosure of cash flow information and non-cash transactions:					
Interest paid in cash	\$	62,988	\$ 22,257	\$	21,537
Property and equipment included in accounts payable and accrued liabilities	φ \$	210,270	\$ 193,378	\$	1,036,240
Acquisition of equipment under debt arrangement	\$		\$ 74,068	Ψ	